Analytical Data
-
Gene name
GSDMD
- Application
-
Alternative Names
(Gasdermin domain-containing protein 1)(GSDMD-NT)(hGSDMD-NTD)(GSDMD-CT)(hGSDMD-CTD)
-
Species
Human
-
Source
E. coli
-
Tag
N- MBP & C- His-Avi
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P57764
-
Expression Region
1-484aa
-
Molecular Weight
100.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Gasdermin D (GSDMD) is a member of the Gasdermin protein family, known for its critical role in mediating pyroptosis, a form of programmed cell death associated with inflammatory responses. Research into GSDMD has gained momentum due to its involvement in various diseases, particularly those linked to chronic inflammation, infection, and autoimmune disorders. Upon cleavage by inflammatory caspases, GSDMD forms pores in the plasma membrane, leading to cell swelling and lysis, which release pro-inflammatory cytokines and danger signals, thus exacerbating tissue damage and inflammation. The understanding of GSDMD's mechanisms has profound implications for therapeutic interventions; targeting its pathways could offer strategies for controlling inflammation in diseases such as sepsis, cardiovascular diseases, and certain cancers. Recent advancements in recombinant protein technology have facilitated the production of GSDMD for functional studies, allowing researchers to investigate its role in cellular processes and interactions with other proteins. Furthermore, studies explore how mutations or dysregulation of GSDMD contribute to disease pathology, highlighting the necessity for further investigation into its structure-function relationship and potential as a drug target. Overall, the robust interest in GSDMD research reflects its significance in both fundamental biology and clinical applications.
